Results 151 to 160 of about 104,006 (269)

An Unusual Motor OFF in Parkinson's Disease

open access: yes
Movement Disorders Clinical Practice, EarlyView.
Shreyashi Jha, Mandar S. Jog
wiley   +1 more source

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology

open access: yesBritish Journal of Pharmacology, EarlyView.
Theorized mechanism of dopamine homeostasis restoration in the nucleus accumbens core induced by a psychedelic intervention. Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive ...
Lucas Wittenkeller   +3 more
wiley   +1 more source

Recent advances in understanding anorexia nervosa. [PDF]

open access: yes, 2019
Anorexia nervosa is a complex psychiatric illness associated with food restriction and high mortality. Recent brain research in adolescents and adults with anorexia nervosa has used larger sample sizes compared with earlier studies and tasks that test ...
DeGuzman, Marisa C   +2 more
core  

3,4‐Methylenedioxymethamphetamine (MDMA) does not induce robust psychomotor activation and 50‐kHz ultrasonic vocalisations in tryptophan hydroxylase 2 (Tph2)‐deficient rats lacking serotonin in the central nervous system

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose 3,4‐Methylenedioxymethamphetamine (MDMA), commonly known as ecstasy, is a psychostimulant with entactogenic properties and known to induce arousal and euphoria. As an amphetamine derivate, MDMA acts on the monoamine systems in the brain and stimulates release of dopamine (DA), noradrenaline (NA) and serotonin (5‐HT), yet their ...
Tianhua Wang   +2 more
wiley   +1 more source

Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Schizophrenia is regarded as a complex and heterogeneous psychiatric disorder, characterised by diverse symptoms and comorbidities, which complicate both clinical management and drug development. Current pharmacological treatment, primarily based on dopamine D2 receptor antagonism or partial agonism, which has not markedly progressed since the
Thi Viet Ha Nguyen   +2 more
wiley   +1 more source

Music in the first days of life [PDF]

open access: yes, 2008
In adults, specific neural systems with right-hemispheric weighting are necessary to process pitch, melody and harmony, as well as structure and meaning emerging from musical sequences. To which extent does this neural specialization result from exposure
Cristina Baldoli   +7 more
core   +1 more source

Vesicular glutamate transporter VGLUT2 expression emerges in substantia nigra dopamine neurons in mouse models of parkinsonism in the absence of neurodegeneration

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Subsets of midbrain dopamine (DA) neurons express the vesicular glutamate transporter VGLUT2 and can release the excitatory neurotransmitter glutamate. VGLUT2+ DA neurons of the substantia nigra pars compacta (SNc) were shown to be more resistant to neurodegeneration in animal models of Parkinson's disease (PD ...
Sivakumar Srinivasan   +2 more
wiley   +1 more source

Dopaminergic and Non-Dopaminergic Value Systems in Conditioning and Outcome-Specific Revaluation [PDF]

open access: yes, 2007
Animals are motivated to choose environmental options that can best satisfy current needs. To explain such choices, this paper introduces the MOTIVATOR (Matching Objects To Internal Values Triggers Option Revaluations) neural model.
Bullock, Daniel   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy